Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.81 |
| ▸ | F3 | P13726 | 1/20 | 0.81 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.81 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.81 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.81 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.81 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.81 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.81 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.81 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.69 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.60 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.60 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzamide SCHEMBL594793 | 0.92 | F7 (0.88) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL675207 | 0.92 | F7 (0.96) | F7F3SARM1SIRT2SIRT6 | |
| Biphenyl SCHEMBL20779095 | 0.91 | F7 (0.67) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL2926 | 0.90 | — | — | |
| Niacinamide SCHEMBL29624874 | 0.90 | — | — | |
| Niacinamide SCHEMBL460466 | 0.90 | F7 (1.00) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL19978192 | 0.90 | — | — | |
| Niacinamide SCHEMBL28589259 | 0.89 | F7 (0.81) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL29596610 | 0.89 | F7 (0.81) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL2745101 | 0.89 | F7 (0.88) | F7F3SARM1SIRT2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2023924-B1 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-08-03 | — | — | EP | disclosed |
| US-8119652-B2 | Aryl-fused spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090239849-A1 | Aryl-Fused Spirocyclic Compounds | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090105264-A1 | Substituted Nicotinamide Compounds | MERCK SHARP & DOHME CORP. | 2009-04-23 | — | — | US | disclosed |
| EP-2023924-A2 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | Merck & Co., Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1945028-A2 | SUBSTITUTED NICOTINAMIDE COMPOUNDS | Merck & Co., Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007136605-A2 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007055942-A2 | SUBSTITUTED NICOTINAMIDE COMPOUNDS | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239849-A1 | Aryl-Fused Spirocyclic Compounds | HDAC1, BRDT, HDAC5 | F7 4796/4885F3 2708/4885SARM1 783/4885 |
| US-20090105264-A1 | Substituted Nicotinamide Compounds | SIRT1, NQO1, TXNRD2 | F7 4571/4885F3 999/4885SARM1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.